Patent Application
20090105135
The present invention relates to a cancer therapeutic agent for a bladder cancer, a colon cancer, and peritoneal metastasis of a stomach cancer and a pancreatic cancer.
Diphtheria toxin or its mutant such as CRM197 has an activity to inhibit the binding of HB-EGF to EGF receptor by binding to an EGF-like domain in soluble and non-soluble (membrane-anchored) HB-EGF. A receptor binding domain in diphtheria toxin is involved in this binding.
Various studies have been performed on anti-cancer effects of CRM197. For example, it is described in Patent Document 1 that CRM197 is effective for a breast cancer, an ovarian cancer, a prostate cancer and a thyroid cancer. It is disclosed in Non-patent Literature 1 that when CRM197 was administered to patients with cancer having the metastasis, complete responses were observed in the breast cancer and a neuroblastoma, but the cancer progressed in cases of a non-small cell lung cancer, the colon cancer and the bladder cancer.
No effective anticancer agent is available for the peritoneal metastasis of the stomach cancer and the pancreatic cancer, whose prognosis is known to be poor. No effect of diphtheria toxin or its mutant such as CRM197 on these cancers have been known.
It is an object of the present invention to provide an anticancer agent effective for a bladder cancer, a colon cancer, and peritoneal metastasis of a stomach cancer and a pancreatic cancer.
As a result of an extensive study on anti-tumor effects of CRM197, the present inventor has found that CRM197 is effective for a bladder cancer, a colon cancer, or peritoneal metastasis of a stomach cancer and a pancreatic cancer.
The present invention relates to the following cancer therapeutic agents.
[1] A cancer therapeutic agent comprising as an active ingredient a substance which inhibits the binding of HB-EGF to EGF receptor by binding to HB-EGF,
wherein the active ingredient is a mutant of diphtheria toxin which is a polypeptide having an activity to inhibit the binding of HB-EGF to EGF receptor and substantially having no toxicity of diphtheria toxin
and wherein a cancer is selected from the group consisting of a colon cancer, a bladder cancer and a peritoneal metastatic cancer.
[2] The cancer therapeutic agent according to [1] which is a therapeutic agent for the bladder cancer.
[3] The cancer therapeutic agent according to [1] which is a therapeutic agent for the colon cancer.
[4] The cancer therapeutic agent according to [1] which is a therapeutic agent for the peritoneal metastatic cancer.
[5] The cancer therapeutic agent according to [4] wherein the peritoneal metastatic cancer is the cancer which has metastasized from the stomach cancer or the pancreatic cancer and has spread peritoneally.
[6] The cancer therapeutic agent according to any of [1] to [5] wherein the active ingredient is CRM197.
According to the present invention, it is possible to effectively treat the bladder cancer, the colon cancer, and the peritoneal metastasis of the stomach cancer and the pancreatic cancer.
The present invention relates to a therapeutic agent comprising as an active ingredient a substance which inhibits the binding of HB-EGF to EGF receptor by binding to HB-EGF, particularly a polypeptide which is diphtheria toxin mutant having an activity to inhibit the binding of HB-EGF to EGF receptor and substantially having no toxicity of diphtheria toxin, for treating at least one cancer selected from the group consisting of a colon cancer, a bladder cancer or peritoneal metastatic cancers of a stomach cancer and a pancreatic cancer.
The polypeptide comprising a receptor binding domain of diphtheria toxin is preferable as an example of the above substance. The particularly preferable above substance is either CRM197 or DT52E148K. For amino acid numbers in CRM197, the amino acid (Gly) at position 26 was numbered as No. 1 by removing a signal sequence (1 to 25) in an amino acid sequence in SEQ ID NO:1.
The receptor binding domain in diphtheria toxin can inhibit the binding of HB-EGF to EGF receptor by binding to HB-EGF. A polypeptide having one or more (e.g., several to several tens of) amino acid deletions, substitutions, insertions or additions in a catalytic action domain of diphtheria toxin to impair a part or all of the catalytic action is preferable as an example of the above polypeptide because of its low toxicity. The signal sequence of 25 amino acid residues may or may not be included.
In one preferable embodiment of the present invention, the above substance includes any of the following polypeptide (a), (b) or (c) having the activity to inhibit the binding of HB-EGF to EGF receptor:
(a) a polypeptide composed of parts of diphtheria toxin and containing at least the receptor binding domain of diphtheria toxin;
(b) a polypeptide composed of an amino acid sequence having one or more (e.g., several or several tens of) amino acid deletions, substitutions or additions in the receptor binding domain in the polypeptide (a); or
(c) a complex polypeptide containing either the protein (a) or (b).
The receptor binding domain generally indicates a region from the position 378 to a C terminus (position 535), but it has been reported that a region of about 53 amino acid residues in a C terminal side has a receptor binding ability (J. Biol. Chem., 265:7331-7337, 1990).
Diphtheria toxin mutants such as CRM197 and DT52E148K are preferable as the active ingredient of the cancer therapeutic agent of the present invention because they have the low toxicity.
It is preferable in terms of eliminating side effects and enhancing safety that a toxic level in the substance of the present invention is equivalent to or less than that of CRM197. However, the present invention suggests that the toxicity contributes to the effect of a carcinostatic agent, and thus, it is also preferable in terms of enhancing the carcinostatic effect to have the toxicity at extremely low level equivalent to that of CRM197. Therefore, depending on a preparation formula, it is possible to appropriately select the toxic level of diphtheria toxin.
The toxic level of diphtheria toxin can be controlled by mutating the catalytic action domain essential for ADP ribosylation or deleting the parts or all of the catalytic action domain. In addition to this, those having a mutation in a transmembrane domain present between the catalytic action domain and the receptor binding domain become non-toxic or low toxic because the catalytic domain can not be internalized in cytoplasm. Therefore, it is likely to be able to also use diphtheria toxin having the mutation in this region as the carcinostatic agent.
The polypeptide containing the amino acid sequence from the position 378 to the position 535 corresponding to the receptor binding domain in the amino acid sequence of diphtheria toxin has the activity to inhibit the binding of HB-EGF to EGF receptor in the active ingredient of the present invention.
The preferable substance which is the active ingredient of the present invention includes (i) diphtheria toxin mutant keeping the receptor binding domain of diphtheria toxin and mutating (partial or total substitution, deletion insertion or addition) the catalytic action domain. Specific examples of such a mutant include CRM197, DT52E148K and GST-DT. These mutants substantially have no toxicity of diphtheria toxin and inhibit the binding of HB-EGF to EGF receptor. CRM 197 is the mutant having the mutation from Gly to Glu at position 52 when counted with the exception of the signal sequence of 25 amino acid residues; DT52E148K is the mutant having the mutation from Glu to Lys at position 148 in addition to the above mutation when counted with the exception of the signal sequence; and GST-DT is the protein containing the amino acid residues from positions 378 to 535 when counted with the exception of the signal sequence, which is bound to GST (glutathione S-transferase). The amino acid sequence (first 25 amino acid residues compose the signal sequence) of CRM197 is shown in SEQ ID NO:1, and a base sequence encoding it is shown in SEQ ID NO:2.
It has been already reported that CRM197 does not have the toxicity of diphtheria toxin, i.e., does not have an ADP ribosylation activity (T. Uchida and A. M. Pappenheimer Jr. (1972) Science 175, 901-903). It has been also known that the 148K mutant having the mutation at 148E has only the extremely weak activity (J. T. Barbieri and R. J. Collier (1987) Infect. Immun. 55, 1647-1651). DT52E148K which is a double mutant further having a 148K mutation in CRM197 which is a 52E mutant is preferable as the safer mutant.
A fragment containing the receptor binding domain can be prepared by synthesizing a DNA sequence of a receptor binding domain portion by PCR using a gene (Pβ197) encoding CRM197 incorporated in a plasmid as a template, inserting this in a multicloning site in an expression vector (pGEX-3X, pQE-30) for synthesizing a GST fusion protein or a histidine tag, incorporating the resulting plasmid in Escherichia coli and synthesizing the gene encoded by the plasmid in Escherichia coli.
The mutant having the mutation in the catalytic action domain can be made as follows. A CRM197 region is synthesized by PCR with the gene (Pβ197) encoding CRM197 incorporated in the plasmid as the template using as a primer a portion to be mutated. The primer is synthesized by introducing a point mutation so as to be mutated, and used. The mutant can be made by incorporating the synthesized DNA into a gene expression vector (pET-22b) for Escherichia coli, transforming Escherichia coli with the vector to express the mutant in Escherichia coli.
The therapeutic agent of the present invention is effective for the treatment of primary foci of the bladder cancer and the colon cancer, and metastatic foci (peritoneal metastasis) of the stomach cancer and the pancreatic cancer.
The therapeutic agent of the present invention is effective for the treatment of the cancer in which the expression of HB-EGF has been especially enhanced among growth factors in the EGF family.
The therapeutic agent of the present invention can be directly formulated from the above active ingredient, or can be formulated by combining the ingredient with a pharmaceutically acceptable carrier for pharmaceuticals.
The above therapeutic agent can be administered orally or parenterally (e.g., intravenous, intramuscular, intraperitoneal, subcutaneous or intradermal injection, or intrarectal administration, permucosal administration, administration via respiratory tract). When applied to peritoneally spread malignant tumors such as peritoneal metastasis of the stomach cancer and the pancreatic cancer, it is preferable in terms of being directly carried to the cancer cells to administer by intraperitoneal injection.
Formulations of the pharmaceutical composition orally administered can include but are to limited to, for example, tablets, granules, capsules, powders, liquids, suspensions and syrups, and the formulations of the pharmaceutical composition parenterally administered can include but are not limited to, for example, injectable agents, infusion agents, suppositories and percutaneous absorbers.
Types of additives for the preparation used for producing the therapeutic agent are not particularly limited and can be appropriately selected by those skilled in the art. For example, excipients, disintegrants or disintegrant aids, binders, lubricants, coating agents, bases, dissolving agents or dissolving agent aids, dispersants, suspending agents, emulsifiers, buffers, antioxidants, preservatives, tonicity agents, pH adjusters, dissolving agents and stabilizers can be used, and individual specific ingredients used for these purposes are well known to those skilled in the art.
As the additives for the preparation used for preparing the preparation for the oral administration, the excipient such as glucose, lactose, D-mannitol, starch or crystalline cellulose; the disintegrant or the disintegrant aid such as carboxymethylcellulose, starch or calcium carboxymethylcellulose; the binder such as hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl pyrrolidone or gelatin; the lubricant such as magnesium stearate or talc; coating agent such as hydroxypropylmethylcellulose, sucrose, polyethylene glycol or titanium oxide; and the base such as petrolatum, liquid paraffin, polyethylene glycol, gelatin, kaolin, glycerine, purified water and hard fat can be used.
As the additives for the preparation which can be used for preparing the preparation for the injection or the infusion, the dissolving agent or the dissolving aid such as distilled water for the injection, saline and propylene glycol which can constitute an aqueous injectable agent or an injectable agent dissolved in use; the tonicity agent such as glucose, sodium chloride, D-mannitol and glycerine; and the pH adjuster such as inorganic acids, organic acid, inorganic bases or organic bases can be used.
Although an amount of the active ingredient contained in the therapeutic agent of the present invention varies depending on a dosage form or an administration route of the therapeutic agent and can not be defined rigidly, it can be typically determined by appropriately selecting from the range of about 0.0001% to 70% in the final preparation.
The therapeutic agent of the present invention can be administered to mammalian animals including human beings, particularly the human beings.
The amount of the therapeutic agent of the present invention to be administered should be appropriately increased or decreased depending on the condition e.g., an age, gender, body weight and symptoms of the patient, and the administration route, and is preferably in the range of about 1 μg to 50 mg per 1 kg of the body weight as the amount of the active ingredient per day per adult. The pharmaceutical in the above amount to be administered may be administered once daily or administered by dividing into several times. The pharmaceutical may be administered once weekly over 6 to 8 weeks, or administered every other day over 2 to 3 weeks, or administered daily for 10 to 14 days.
As the carcinostatic agent capable of being combined with the cancer therapeutic agent of the present application, taxol, taxotere, 5-FU, cisplatin, carboplatin, adriamycin and camptothecin and the like are exemplified.
The present invention will be described below in detail based on Examples, but it goes without saying that the present invention is not limited to these Examples.
A peritoneal spread model. Human stomach cancer cell lines, MKN28, MKN45 and MKN74 cells at 1×107 were intraperitoneally inoculated to nude mice, and CRM197 was intraperitoneally administered five times (50 mg/kg/week). On the 6th week after the inoculation, the entire peritoneal spread foci were removed, and their total weight was measured (
A tumorigenicity experiment using nude mice was performed. Human bladder cancer cell line, KK47 cells cultured in RPMI+10% FBS were washed with EDTA/PBS(−), and collected using 0.25% trypsin. The cells were washed twice with RPMI+10% FBS and twice with RPMI (serum free), and the cells at 5×106 were added to 250 μL of RPMI (containing the serum). This was inoculated to the back of nude mice by injecting subcutaneously. In one group of the nude mice, CRM197 in an amount of 50 mg/kg/week was administered intraperitoneally from the 7th day after inoculating the cells. CRM197 was administered once a week over 3 weeks. The nude mice to which no CRM197 had been administered were used as the control. A relationship of an administration time and a tumor volume is shown in
A tumorigenicity experiment using nude mice was performed. Human colon cancer cell line, HT29 or HCT116 cells (available from American Type Culture Collection [ATCC]) cultured in RPMI+10% FBS were washed with EDTA/PBS(−), and collected using 0.25% trypsin. The cells were washed twice with RPMI+10% FBS and twice with RPMI (serum free), and the cells at 5×106 were added to 250 μL of RPMI (containing the serum). This was inoculated to the back of nude mice by injecting subcutaneously. In one group of the nude mice, CRM197 in an amount of 50 mg/kg/week was administered intraperitoneally from the 7th day after inoculating the cells. CRM197 was administered once a week over 3 weeks. The nude mice to which no CRM197 had been administered were used as the control. The relationship of the administration time and the tumor volume is shown in
A peritoneal spread model. Human pancreatic cancer cell line, PANC1 cells at 1×107 were intraperitoneally inoculated to nude mice, and CRM197 was intraperitoneally administered five times (50 mg/kg/week). On the 6th week after the inoculation, the entire peritoneal spread foci were removed, and their total weight was measured (
From results in these Examples, it has been found that the administration of CRM197 inhibited the tumor growth in all cases.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2005-181314 | Jun 2005 | JP | national |
| 2006-027581 | Feb 2006 | JP | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/JP2006/312321 | 6/20/2006 | WO | 00 | 12/14/2007 |
